YD Bio is a biotechnology business that focuses on developing solutions for early disease detection, regenerative medicine, and clinical healthcare. It combines strong scientific foundations with practical application in order to solve major medical gaps. Aiming to translate advanced studies into products that benefit patients and clinicians.

The company's main areas of focus are non-invasive early cancer detection by using DNA methylation-based liquid biopsy technologies, dry eye care products, and regenerative medicines based on exosomes that are produced from limbal stem cells. These platforms show YD Bio's dedication to developing targeted and lasting medicinal solutions. In addition, YD Bio contributes to worldwide clinical research by offering excellent clinical trial medications and scientific wellness products to pharmaceutical and biotechnology companies.

YD Bio expands with strategic partnerships, like collaboration in exosome research and the supply of CAP-accredited, CLIA-certified laboratory services in the US. Its broad range shows its dedication to quality, safety, and innovation across many healthcare industries. With a goal to improve patient outcomes, YD Bio combines scientific understanding, regulatory standards and worldwide cooperation to provide meaningful and accessible healthcare solutions.

Products Offered by YD Bio

Laboratory Developed Test Service

YD Bio's Laboratory Developed Test (LDT) services intend to make cancer detection and monitoring easier and faster. It uses modern liquid biopsy technology to assess cfDNA and DNA methylation biomarkers in a blood sample. This offers clear and useful data that supports quicker clinical choices and better patient outcomes.

For pancreatic cancer, YD Bio provides a blood-based early detection test that addresses the difficulty of late diagnosis, which is the main cause of poor survival rates. The test detects cancer-related signals in the circulation by DNA methylation analysis, allowing diagnosis even before symptoms occur. Preclinical investigations conducted in Taiwan and Western populations have shown high accuracy, with detection rates of 93.8% in early-stage disease (Stages I and II) and 99.0% in advanced stages (Stages III and IV). The test just requires a standard blood draw, produces quick results, and is a more accessible and affordable option than scanning or surgical biopsy treatments. It is now available as an LDT from YD Bio's CAP-accredited and CLIA-certified laboratory.

YD Bio is developing the EG-Breast Blood Test-P1 for breast cancer patients to help with the continued tracking of the disease during and after treatment. By tracking specific methylation biomarkers like GCM2 and TMEM240, the test offers real-time information about treatment response and recurrence risk. The breast cancer tracking test is currently in clinical testing and has shown good early results. Together, these offerings highlight YD Bio's dedication to practical, patient-friendly cancer treatment solutions.

Eye Care

YD Bio's Eye Care portfolio, referred to as Exovisse, focuses on offering simple, safe, and effective solutions for patients who have dry eyes and contact lens discomfort. These items are designed for everyday use and stress comfort, ease of use, and eye safety for better lasting eye health.

Exovisse Artificial Tears are aimed at reducing dryness and irritation by returning moisture to the eye surface. The drop-based structure provides slight hydration to ease burning, gritty feelings, and discomfort caused by environmental causes, long hours of screen time, or contact lens wear. The drops are safe and simple to incorporate into a daily routine, which makes them perfect for sensitive eyes, especially for those who wear contact lenses. The formulation meets FDA OTC Monograph M018 requirements, giving it a dependable and accessible solution for dry eye treatment.

Exovision contact lenses are made of excellent hydrogel and silicone hydrogel materials, which improve everyday wear comfort. These lenses have a hydrating structure, helping users keep their eyes hydrated throughout the day. It also helps to reduce the dryness that is commonly associated with regular contact lenses. Developed for high tolerance, they provide consistent comfort and performance in a wide range of daily situations. Exovisse artificial tears and contact lenses show YD Bio's dedication to practical, scientifically proven eye care products that improve comfort and quality of life.

Clinical Trial Drug Distribution

YD Bio's Clinical Trial Drug Distribution service offers dependable, complete solutions for collecting, handling, and distributing investigational medications to pharmaceutical, biotech, and research organizations worldwide. All products are controlled by Good Manufacturing Practice (GMP) guidelines, ensuring high quality, safety, and regulatory compliance in worldwide clinical investigations.

The program supports a number of clients, including major pharmaceutical corporations, CROs and academic institutions. YD Bio offers personalized options to meet the particular goals of each study, from fast delivery to consistent medication supply across different areas. Built for dependability and scalability, the platform allows research teams to confidently advance clinical programs while ensuring their medications are managed safely and efficiently.

YD Bio is currently operating and serving worldwide trials, and it is expanding its distribution network to meet rising demand and facilitate new international research collaborations. This service shows YD Bio's dedication to advancing healthcare innovation by ensuring that vital treatments reach patients and studies in need in a safe, dependable, and timely manner.

Dr. Ethan Shen | Chairman of the Board and CEO

Dr. Ethan Shen, PhD, is Chairman of the Board and CEO of YD Bio, leading the company in cancer diagnostics, eye care, and exosome therapies. With over 20 years in biotech, Shen co-developed an anti–PD-L1 cancer vaccine and supports early-stage research and innovation. He is committed to turning scientific discoveries into real-world healthcare solutions.

"YD Bio is dedicated to developing advanced detection and therapeutic technologies that transform healthcare. Its work spans non-invasive early cancer detection, regenerative approaches in ophthalmology, and exosome-based therapeutics."